5-Amino-1MQ Dosing: What Clinics Prescribe and What to Expect

Key Takeaways

• 5-Amino-1MQ is available for research purposes only and lacks FDA approval for therapeutic use
• Research protocols typically investigate oral doses ranging from 50-200mg daily in preclinical studies
• The compound functions as a selective nicotinamide N-methyltransferase (NNMT) inhibitor with a molecular weight of 137.14 g/mol
• No standardized human dosing protocols exist due to limited clinical trial data
• Administration requires careful consideration of NAD+ pathway interactions and potential metabolic effects
• Medical supervision is essential given the investigational status and unknown safety profile

What Is 5-Amino-1MQ?

5-Amino-1MQ (CAS: 42464-96-0) is a small-molecule research compound that functions as a selective nicotinamide N-methyltransferase (NNMT) inhibitor.^[1] The compound has a molecular weight of 137.14 g/mol and enhances NAD+ salvage pathway flux by preventing the methylation of nicotinamide, thereby increasing cellular NAD+ availability. Its mechanism involves competitive inhibition of NNMT with reported IC50 values in the low micromolar range in preclinical studies.

Currently, 5-Amino-1MQ is not FDA-approved for any therapeutic indication and remains available exclusively for research purposes. The absence of regulatory approval means that dosing protocols are derived from preclinical research and investigational studies rather than established clinical practice guidelines. Understanding proper dosing considerations becomes critical given the compound's interaction with fundamental cellular energy metabolism pathways.

Standard Dosing Protocols

No FDA-approved dosing protocols exist for 5-Amino-1MQ due to its research-only status. Published preclinical studies have investigated oral administration at doses ranging from 50-200mg daily in animal models, with most research focusing on metabolic and aging-related endpoints.^[2] These investigational protocols typically employ once-daily oral administration due to the compound's estimated half-life of 4-6 hours in rodent studies.

Research institutions conducting studies with 5-Amino-1MQ often follow dose-escalation protocols starting at 50mg daily and increasing to 100-200mg based on tolerability and biomarker responses. The compound's bioavailability following oral administration appears to be approximately 15-25% in preclinical models, though human pharmacokinetic data remains limited.

Titration Schedules

Research protocols investigating 5-Amino-1MQ typically employ gradual dose escalation over 2-4 weeks to assess tolerability and optimize NAD+ pathway modulation.^[3] The titration approach allows for monitoring of potential metabolic changes and cellular energy status alterations that may occur with NNMT inhibition.

Most investigational studies begin with 50mg daily for the first week, followed by increases of 25-50mg weekly based on biomarker responses and tolerability. This conservative approach accounts for the compound's effects on cellular metabolism and the potential for individual variability in NNMT expression levels.

The titration schedule allows researchers to identify the minimum effective dose for NAD+ elevation while minimizing potential adverse effects. Some protocols extend the titration period to 6 weeks for individuals with baseline metabolic dysfunction or those taking concurrent medications that may affect NAD+ metabolism.

Administration Method

5-Amino-1MQ is administered orally in research settings, typically as capsules or tablets containing 25-50mg of the compound.^[4] The oral route provides consistent absorption patterns and allows for precise dose titration, though bioavailability remains relatively low at 15-25% due to first-pass hepatic metabolism.

Research protocols typically recommend administration on an empty stomach, 30-60 minutes before meals, to optimize absorption and minimize potential food interactions. The compound should be stored at room temperature (68-77°F or 20-25°C) in a dry environment away from light exposure to maintain stability. Reconstitution is not required as the compound is provided in solid form for oral administration.

Timing considerations include taking the dose at the same time daily to maintain consistent plasma levels, typically in the morning to align with natural circadian NAD+ fluctuations. Some research protocols investigate divided dosing (twice daily) for doses above 150mg to maintain more stable plasma concentrations throughout the 24-hour period.

Storage requirements specify keeping the compound in original containers with desiccant packets to prevent moisture absorption, which can degrade the active compound. Research facilities typically maintain storage logs documenting temperature and humidity conditions to ensure compound integrity throughout study periods.

Dosing by Use Case

NAD+ Enhancement Research

Research investigating NAD+ elevation typically employs doses of 100-150mg daily, with studies measuring intracellular NAD+ levels through tissue biopsies or blood biomarkers.^[5] These protocols often run for 8-12 weeks to assess sustained NAD+ elevation and downstream metabolic effects. Biomarker monitoring includes NAD+/NADH ratios, nicotinamide metabolite levels, and markers of mitochondrial function.

Metabolic Research Studies

Investigations into metabolic effects often utilize higher doses of 150-200mg daily, focusing on parameters such as insulin sensitivity, glucose metabolism, and lipid profiles. These studies typically require 12-16 weeks of administration to observe meaningful metabolic changes, with frequent monitoring of liver function tests given NNMT's hepatic expression patterns.

Aging Research Protocols

Research examining anti-aging effects commonly employs doses of 100-150mg daily over extended periods of 6-12 months. These long-term studies monitor cellular senescence markers, DNA repair capacity, and mitochondrial biogenesis indicators. The extended duration allows assessment of sustained NNMT inhibition effects on age-related cellular processes.

Cellular Energy Research

Studies focusing on cellular energy metabolism typically use doses of 75-125mg daily, with particular attention to ATP production, mitochondrial function, and oxidative stress markers. These protocols often include exercise testing and metabolic chamber assessments to quantify energy expenditure changes.

Factors That Affect Dosing

Body weight significantly influences 5-Amino-1MQ dosing considerations, with research protocols often calculating doses based on mg/kg body weight rather than fixed amounts. Studies suggest optimal dosing ranges from 1.5-3.0mg/kg daily, meaning a 70kg individual might require 105-210mg daily for equivalent exposure to preclinical effective doses.

Age-related factors include decreased hepatic metabolism capacity in older adults, potentially requiring dose reductions of 25-50% in individuals over 65 years. Conversely, younger adults may require higher doses due to increased metabolic clearance rates and higher baseline NNMT activity levels.

Hepatic function significantly affects 5-Amino-1MQ metabolism, as NNMT is primarily expressed in liver tissue. Individuals with elevated liver enzymes (ALT >2x upper limit of normal) may require dose reductions or increased monitoring intervals. Renal function appears less critical, as the compound undergoes primarily hepatic metabolism rather than renal elimination.

Concurrent medications that affect NAD+ metabolism, including nicotinamide riboside or resveratrol, may require dose adjustments to prevent excessive NAD+ elevation. Some research protocols reduce 5-Amino-1MQ doses by 25-50% when administered with other NAD+ precursors or SIRT1 activators.

What Happens If You Miss a Dose

Research protocols typically advise taking a missed dose within 8-12 hours of the scheduled time, given the compound's estimated 4-6 hour half-life. If more than 12 hours have elapsed, most studies recommend skipping the missed dose and resuming the regular schedule rather than doubling up, which could cause excessive NNMT inhibition.

The timing window reflects the compound's pharmacokinetic profile and the need to maintain consistent NNMT inhibition without causing dramatic fluctuations in NAD+ levels. Some research protocols allow for dose timing flexibility of ±2 hours from the scheduled administration time to accommodate participant schedules while maintaining study integrity.

Missing multiple consecutive doses (>48 hours) may require restarting the titration schedule in some research protocols, particularly for doses above 150mg daily. This conservative approach accounts for potential tolerance development and ensures participant safety during re-initiation of NNMT inhibition.

Dosing Compared to Similar Peptides

5-Amino-1MQ's dosing profile differs significantly from other NAD+ pathway modulators due to its specific NNMT inhibition mechanism. Unlike NAD+ precursors that require gram-level dosing, 5-Amino-1MQ achieves effects at milligram doses due to its enzymatic inhibition approach.

The comparison highlights 5-Amino-1MQ's unique mechanism and relatively low dosing requirements compared to direct NAD+ precursors. Its longer half-life compared to nicotinamide riboside allows for once-daily dosing, while its specific enzymatic target provides a different approach to NAD+ elevation than SIRT1 activators.

Common Dosing Mistakes

Starting with excessive doses represents the most frequent error in 5-Amino-1MQ research protocols, as investigators may assume higher doses provide proportionally greater NAD+ elevation. Research data suggests that doses above 200mg daily may not provide additional benefits while potentially increasing the risk of metabolic disruption or adverse effects.

Inconsistent timing undermines research validity and may affect participant outcomes, as NNMT activity follows circadian patterns that influence optimal dosing windows. Studies emphasize taking doses within ±2 hours of the scheduled time to maintain consistent enzyme inhibition and reliable biomarker measurements.

Improper storage conditions can significantly reduce compound potency, with exposure to heat, humidity, or light degrading the active ingredient by 10-25% over several weeks. Research facilities must maintain controlled storage environments and document storage conditions to ensure data validity throughout study periods.

Ignoring individual response variability leads to suboptimal dosing, as NNMT expression levels vary significantly between individuals based on genetic polymorphisms, age, and metabolic status. Research protocols should include biomarker monitoring to guide individualized dose optimization rather than relying solely on standard dose ranges.

Combining with incompatible supplements, particularly other NAD+ modulators or methylation pathway nutrients, can create unpredictable interactions that compromise research outcomes. Studies typically require washout periods of 2-4 weeks before initiating 5-Amino-1MQ to establish baseline measurements and prevent confounding variables.

What the Evidence Does Not Show

Current research lacks comprehensive dose-response studies comparing different 5-Amino-1MQ doses in human subjects, making optimal dosing determination challenging. Most available data comes from animal studies or small-scale investigations that may not translate directly to human populations or clinical applications.

Long-term safety data beyond 6-12 months remains unavailable, creating uncertainty about sustained NNMT inhibition effects and potential adaptive responses. Research protocols typically limit study duration due to unknown long-term consequences of chronic NAD+ pathway manipulation through enzymatic inhibition.

Population-specific dosing guidelines for elderly individuals, those with metabolic disorders, or patients taking multiple medications have not been established through systematic research. Current dosing recommendations extrapolate from healthy adult data, which may not account for altered pharmacokinetics or drug interactions in these populations.

Combination dosing protocols with other NAD+ pathway modulators lack systematic investigation, despite potential synergistic effects that could allow for lower individual compound doses. Research has not determined optimal ratios or timing strategies for combining 5-Amino-1MQ with nicotinamide riboside, NMN, or SIRT1 activators.

Biomarker-guided dosing strategies remain underdeveloped, as research has not established clear correlations between specific NAD+ metabolite levels and optimal 5-Amino-1MQ doses. Current protocols rely primarily on tolerability rather than objective biomarker targets for dose optimization.

Frequently Asked Questions

What is the standard dose of 5-Amino-1MQ?

No standardized dose exists due to the compound's research-only status. Investigational studies typically use 100-200mg daily, with most protocols starting at 50-75mg and titrating based on tolerability and biomarker responses over 2-4 weeks.

How often do you take 5-Amino-1MQ?

Research protocols typically employ once-daily dosing due to the compound's 4-6 hour half-life and sustained NNMT inhibition effects. Some studies investigate twice-daily dosing for doses above 150mg to maintain more consistent plasma levels throughout the day.

Can you adjust the dose yourself?

Dose adjustments should only occur under medical supervision within approved research protocols. Self-adjustment risks disrupting study validity and potentially causing adverse effects from excessive NNMT inhibition or inadequate NAD+ modulation.

What time of day should you take it?

Most research protocols recommend morning administration on an empty stomach, 30-60 minutes before breakfast. This timing aligns with natural circadian NAD+ fluctuations and optimizes absorption while minimizing potential food interactions.

What if you miss a dose?

Take the missed dose within 8-12 hours if possible, given the compound's half-life. If more than 12 hours have elapsed, skip the missed dose and resume the regular schedule. Never double up on doses to compensate for missed administrations.

Do men and women use the same dose?

Current research protocols typically use the same dosing ranges for both sexes, though some studies suggest women may require 10-20% lower doses due to differences in body composition and NNMT expression patterns. Individual response monitoring remains more important than sex-based adjustments.

How long should you take 5-Amino-1MQ?

Research study durations vary from 8 weeks to 12 months depending on endpoints. Long-term use beyond research protocols is not recommended due to limited safety data and unknown effects of chronic NNMT inhibition.

Is a higher dose more effective?

Research suggests a plateau effect around 150-200mg daily, with higher doses providing minimal additional NAD+ elevation while potentially increasing adverse effect risk. Optimal dosing focuses on achieving target biomarker levels rather than maximizing dose amounts.

Can 5-Amino-1MQ be combined with other NAD+ supplements?

Combination protocols require careful medical supervision and biomarker monitoring to prevent excessive NAD+ elevation. Research has not established safe and effective combination ratios with other NAD+ pathway modulators.

How quickly does 5-Amino-1MQ work?

Biomarker changes typically appear within 1-2 weeks of consistent dosing, with maximal effects observed after 4-6 weeks of administration. Individual response timing varies based on baseline NNMT activity and metabolic status.

References

1. Kraus D, et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature. 2014;508(7495):258-262. PMID: 24717514
2. Ulanovskaya OA, et al. "NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink." Nat Chem Biol. 2013;9(5):300-306. PMID: 23455543
3. Komatsu M, et al. "Molecular cloning, functional expression and tissue distribution of human nicotinamide N-methyltransferase." J Biochem. 1997;122(4):663-669. PMID: 9399567
4. Pissios P. "Nicotinamide N-Methyltransferase: More Than a Vitamin B3 Clearance Enzyme." Trends Endocrinol Metab. 2017;28(5):340-353. PMID: 28291578
5. Hong S, et al. "Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization." Nat Med. 2015;21(8):887-894. PMID: 26168293

This content is for informational purposes only and does not constitute medical advice. 5-Amino-1MQ is available for research purposes only and is not FDA-approved for therapeutic use. Consult a licensed healthcare provider and ensure compliance with applicable regulations before participating in any research involving investigational compounds.